Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

NCT02462538 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
3
Enrollment
OTHER
Sponsor class

Stopped Due to slow recruitment, recruitment of new patients was stopped, FU was completed for enrolled patients

Conditions

Interventions

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie